These findings demonstrate that CD147+ EVs are predominantly released by cancer cells and from an early stage, and raise the possibility that increased levels of CD147+ EVs could be a useful indicator of early‐stage and/or low‐volume malignancy. The gene discussed is BSG; the disease is cancer.